The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines

Maurice A. Canham; Amy Van Deusen; Daniel R. Brison; Paul A. De Sousa; Janet Downie; Liani Devito; Zoe A. Hewitt; Dusko Ilic; Susan J. Kimber; Harry D. Moore; Helen Murray; Tilo Kunath

doi:10.1038/srep17258

The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines

Maurice A. Canham, Amy Van Deusen, Daniel R. Brison, Paul A. De Sousa, Janet Downie, Liani Devito, Zoe A. Hewitt, Dusko Ilic, Susan J. Kimber, Harry D. Moore, Helen Murray, Tilo Kunath^*

^*Corresponding author for this work

Women & Children's Health

Research output: Contribution to journal › Article › peer-review

46 Citations (Scopus)

Abstract

The application of human embryonic stem cell (hESC) derivatives to regenerative medicine is now becoming a reality. Although the vast majority of hESC lines have been derived for research purposes only, about 50 lines have been established under Good Manufacturing Practice (GMP) conditions. Cell types differentiated from these designated lines may be used as a cell therapy to treat macular degeneration, Parkinson's, Huntington's, diabetes, osteoarthritis and other degenerative conditions. It is essential to know the genetic stability of the hESC lines before progressing to clinical trials. We evaluated the molecular karyotype of 25 clinical-grade hESC lines by whole-genome single nucleotide polymorphism (SNP) array analysis. A total of 15 unique copy number variations (CNVs) greater than 100 kb were detected, most of which were found to be naturally occurring in the human population and none were associated with culture adaptation. In addition, three copy-neutral loss of heterozygosity (CN-LOH) regions greater than 1 Mb were observed and all were relatively small and interstitial suggesting they did not arise in culture. The large number of available clinical-grade hESC lines with defined molecular karyotypes provides a substantial starting platform from which the development of pre-clinical and clinical trials in regenerative medicine can be realised.

Original language	English
Article number	17258
Journal	Scientific Reports
Volume	5
DOIs	https://doi.org/10.1038/srep17258
Publication status	Published - 26 Nov 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/srep17258

Cite this

@article{e81f54b385cb41c3a4df71d422925be3,

title = "The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines",

abstract = "The application of human embryonic stem cell (hESC) derivatives to regenerative medicine is now becoming a reality. Although the vast majority of hESC lines have been derived for research purposes only, about 50 lines have been established under Good Manufacturing Practice (GMP) conditions. Cell types differentiated from these designated lines may be used as a cell therapy to treat macular degeneration, Parkinson's, Huntington's, diabetes, osteoarthritis and other degenerative conditions. It is essential to know the genetic stability of the hESC lines before progressing to clinical trials. We evaluated the molecular karyotype of 25 clinical-grade hESC lines by whole-genome single nucleotide polymorphism (SNP) array analysis. A total of 15 unique copy number variations (CNVs) greater than 100 kb were detected, most of which were found to be naturally occurring in the human population and none were associated with culture adaptation. In addition, three copy-neutral loss of heterozygosity (CN-LOH) regions greater than 1 Mb were observed and all were relatively small and interstitial suggesting they did not arise in culture. The large number of available clinical-grade hESC lines with defined molecular karyotypes provides a substantial starting platform from which the development of pre-clinical and clinical trials in regenerative medicine can be realised.",

author = "Canham, {Maurice A.} and {Van Deusen}, Amy and Brison, {Daniel R.} and {De Sousa}, {Paul A.} and Janet Downie and Liani Devito and Hewitt, {Zoe A.} and Dusko Ilic and Kimber, {Susan J.} and Moore, {Harry D.} and Helen Murray and Tilo Kunath",

year = "2015",

month = nov,

day = "26",

doi = "10.1038/srep17258",

language = "English",

volume = "5",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines

AU - Canham, Maurice A.

AU - Van Deusen, Amy

AU - Brison, Daniel R.

AU - De Sousa, Paul A.

AU - Downie, Janet

AU - Devito, Liani

AU - Hewitt, Zoe A.

AU - Ilic, Dusko

AU - Kimber, Susan J.

AU - Moore, Harry D.

AU - Murray, Helen

AU - Kunath, Tilo

PY - 2015/11/26

Y1 - 2015/11/26

N2 - The application of human embryonic stem cell (hESC) derivatives to regenerative medicine is now becoming a reality. Although the vast majority of hESC lines have been derived for research purposes only, about 50 lines have been established under Good Manufacturing Practice (GMP) conditions. Cell types differentiated from these designated lines may be used as a cell therapy to treat macular degeneration, Parkinson's, Huntington's, diabetes, osteoarthritis and other degenerative conditions. It is essential to know the genetic stability of the hESC lines before progressing to clinical trials. We evaluated the molecular karyotype of 25 clinical-grade hESC lines by whole-genome single nucleotide polymorphism (SNP) array analysis. A total of 15 unique copy number variations (CNVs) greater than 100 kb were detected, most of which were found to be naturally occurring in the human population and none were associated with culture adaptation. In addition, three copy-neutral loss of heterozygosity (CN-LOH) regions greater than 1 Mb were observed and all were relatively small and interstitial suggesting they did not arise in culture. The large number of available clinical-grade hESC lines with defined molecular karyotypes provides a substantial starting platform from which the development of pre-clinical and clinical trials in regenerative medicine can be realised.

AB - The application of human embryonic stem cell (hESC) derivatives to regenerative medicine is now becoming a reality. Although the vast majority of hESC lines have been derived for research purposes only, about 50 lines have been established under Good Manufacturing Practice (GMP) conditions. Cell types differentiated from these designated lines may be used as a cell therapy to treat macular degeneration, Parkinson's, Huntington's, diabetes, osteoarthritis and other degenerative conditions. It is essential to know the genetic stability of the hESC lines before progressing to clinical trials. We evaluated the molecular karyotype of 25 clinical-grade hESC lines by whole-genome single nucleotide polymorphism (SNP) array analysis. A total of 15 unique copy number variations (CNVs) greater than 100 kb were detected, most of which were found to be naturally occurring in the human population and none were associated with culture adaptation. In addition, three copy-neutral loss of heterozygosity (CN-LOH) regions greater than 1 Mb were observed and all were relatively small and interstitial suggesting they did not arise in culture. The large number of available clinical-grade hESC lines with defined molecular karyotypes provides a substantial starting platform from which the development of pre-clinical and clinical trials in regenerative medicine can be realised.

UR - http://www.scopus.com/inward/record.url?scp=84948453046&partnerID=8YFLogxK

U2 - 10.1038/srep17258

DO - 10.1038/srep17258

M3 - Article

AN - SCOPUS:84948453046

SN - 2045-2322

VL - 5

JO - Scientific Reports

JF - Scientific Reports

M1 - 17258

ER -

The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this